FY2029 Earnings Forecast for Evolus Issued By HC Wainwright

Evolus, Inc. (NASDAQ:EOLS) – HC Wainwright issued their FY2029 EPS estimates for shares of Evolus in a research note issued on Wednesday, January 22nd. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of $4.43 per share for the year. HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.63) per share.

Separately, Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Tuesday.

Evolus Stock Performance

Shares of EOLS traded down $0.14 during trading hours on Thursday, hitting $13.99. The stock had a trading volume of 63,950 shares, compared to its average volume of 927,781. The firm has a market capitalization of $885.91 million, a PE ratio of -15.40 and a beta of 1.32. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. Evolus has a 12 month low of $9.25 and a 12 month high of $17.82. The stock has a fifty day moving average price of $11.70 and a 200 day moving average price of $13.75.

Institutional Trading of Evolus

Hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC bought a new stake in shares of Evolus during the 2nd quarter valued at $3,906,000. Charles Schwab Investment Management Inc. raised its holdings in Evolus by 173.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after acquiring an additional 265,635 shares during the period. Ikarian Capital LLC purchased a new position in shares of Evolus in the third quarter valued at about $4,184,000. Walleye Capital LLC bought a new position in shares of Evolus in the third quarter worth about $3,438,000. Finally, Lord Abbett & CO. LLC grew its position in shares of Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after purchasing an additional 188,685 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.